Posted by Michael Wonder on 05 Nov 2020
Lynparza approved in the EU as first-line maintenance treatment with bevacizumab for HRD positive advanced ovarian cancer
5 November 2020 - Patients treated with Lynparza and bevacizumab lived without disease progression for a median of 37.2 months vs. 17.7 months with bevacizumab alone.
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union for the first-line maintenance treatment with bevacizumab of patients with homologous recombination deficient positive advanced ovarian cancer.
